DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine

British Journal of Haematology

Volumn 164, Issue 4, 2014, Pages 613-616

  Moreaux, Jerome ^a,b   Bruyer, Angelique ^b   Veyrune, Jean Luc ^a,b   Goldschmidt, Hartmut ^c   Hose, Dirk ^c   Klein, Bernard ^a,b,d  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIV MONTPELLIER   (France)

Author keywords

Drug sensitivity prediction; Epigenetics; Gene arrays; Gene expression; Myeloma

Indexed keywords

AZACITIDINE;

CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DNA METHYLATION; DNA METHYLATION SCORE; GENE EXPRESSION; HUMAN; HUMAN CELL; LETTER; MYELOMA CELL; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

DRUG SENSITIVITY PREDICTION; EPIGENETICS; GENE ARRAYS; GENE EXPRESSION; MYELOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENOMICS; HUMANS; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS;

EID: 84892983784     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12660     Document Type: Letter

References (10)

1. Heuck, C.J., Mehta, J., Bhagat, T., Gundabolu, K., Yu, Y., Khan, S., Chrysofakis, G., Schinke, C., Tariman, J., Vickrey, E., Pulliam, N., Nischal, S., Zhou, L., Bhattacharyya, S., Meagher, R., Hu, C., Maqbool, S., Suzuki, M., Parekh, S., Reu, F., Steidl, U., Greally, J., Verma, A. & Singhal, S.B. (2013) Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. Journal of Immunology, 190, 2966-2975.
2. Hollenbach, P.W., Nguyen, A.N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S.L., Heise, C. & MacBeth, K.J. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE, 5, e9001.
3. Hose, D., Reme, T., Hielscher, T., Moreaux, J., Messner, T., Seckinger, A., Benner, A., Shaughnessy, J.D. Jr, Barlogie, B., Zhou, Y., Hillengass, J., Bertsch, U., Neben, K., Mohler, T., Rossi, J.F., Jauch, A., Klein, B. & Goldschmidt, H. (2011) Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica, 96, 87-95.
4. Kaiser, M.F., Johnson, D.C., Wu, P., Walker, B.A., Brioli, A., Mirabella, F., Wardell, C.P., Melchor, L., Davies, F.E. & Morgan, G.J. (2013) Global methylation analysis identifies prognostically important epigenetically inactivated tumour suppressor genes in multiple myeloma. Blood, 122, 219-226.
5. Karahoca, M. & Momparler, R.L. (2013) Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clinical Epigenetics, 5, 3.
6. Maes, K., Menu, E., Van Valckenborgh, E., Van Riet, I., Vanderkerken, K. & De Bruyne, E. (2013) Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers, 5, 430-461.
7. Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maiga, S., Hose, D., Goldschmidt, H., Jauch, A., Reme, T., Jourdan, M., Amiot, M. & Pellat-Deceunynck, C. (2011) A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica, 96, 574-582.
8. Moreaux, J., Reme, T., Leonard, W., Veyrune, J.L., Requirand, G., Goldschmidt, H., Hose, D. & Klein, B. (2012) Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Molecular Cancer Therapeutics, 11, 2685-2692.
9. Smith, E.M., Boyd, K. & Davies, F.E. (2009) The potential role of epigenetic therapy in multiple myeloma. British Journal of Haematology, 148, 702-713.
10. Walker, B.A., Wardell, C.P., Chiecchio, L., Smith, E.M., Boyd, K.D., Neri, A., Davies, F.E., Ross, F.M. & Morgan, G.J. (2010) Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 117, 553-562.